Compare T-Rex 2X Long MSTR Daily Target ETF (MSTU) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T-Rex 2X Long MSTR Daily Target ETF vs Zoetis Inc — how do they compare? T-Rex 2X Long MSTR Daily Target ETF trades at $2.16, while Zoetis Inc trades at $75.47 (market cap $31.95B). The key difference: Zoetis Inc pays a 2.78% dividend while T-Rex 2X Long MSTR Daily Target ETF pays none. Which is the better fit depends on your goals.
| MSTU | ZTS | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $92.70 | $156.76 |
52-Week Low | $1.46 | $71.91 |
Market Cap | — | $31.95B |
Enterprise Value | — | $39.24B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTU is trading at $1.98, up 6.45% today, but faces significant headwinds with a bearish technical outlook and concerning fundamental metrics. The leveraged ETF structure has resulted in substantial losses, with reports indicating a 98% decline from November 2024 levels. Technical indicators show mixed signals with bearish moving averages but neutral oscillators, while key financial ratios remain unavailable for analysis.
The outlook remains challenging due to the ETF's leveraged structure and volatility decay. Investment opportunities are limited given the historical performance, while risks include continued erosion of value from daily rebalancing and dependence on MicroStrategy's underlying performance. The fund's viability remains in question based on recent performance trends.
Zoetis (ZTS) trades at $75.33, down 1.61% amid mixed technical signals and ongoing securities litigation. The stock shows strong fundamentals with a 28.03% net margin and 67.75% ROE, supported by consistent revenue growth from $8.1B in 2022 to $9.47B in 2025. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026, with Q2 results pending. Analyst consensus remains positive with a $101.43 price target, though technical indicators show neutral momentum near key support at $75.
The outlook for ZTS is cautiously optimistic given robust profitability and analyst support, but significant legal overhangs and recent earnings volatility present near-term risks. Long-term growth in animal health markets offers upside, yet investors should monitor litigation developments and Q2 earnings for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About T-Rex 2X Long MSTR Daily Target ETF
MSTU is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bullish (long) position in MSTR, a company known for its significant Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on MSTU →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
